- Home
- AXTA vs JAZZ Comparison
AXTA vs JAZZ Comparison
Compare AXTA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXTA
- JAZZ
- Stock Information
- Founded
- AXTA 1910
- JAZZ 2003
- Country
- AXTA United States
- JAZZ Ireland
- Employees
- AXTA N/A
- JAZZ N/A
- Industry
- AXTA Paints/Coatings
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- AXTA Consumer Discretionary
- JAZZ Health Care
- Exchange
- AXTA Nasdaq
- JAZZ Nasdaq
- Market Cap
- AXTA 7.2B
- JAZZ 7.3B
- IPO Year
- AXTA 2014
- JAZZ 2007
- Fundamental
- Price
- AXTA $32.66
- JAZZ $108.98
- Analyst Decision
- AXTA Buy
- JAZZ Strong Buy
- Analyst Count
- AXTA 15
- JAZZ 13
- Target Price
- AXTA $41.33
- JAZZ $181.85
- AVG Volume (30 Days)
- AXTA 2.6M
- JAZZ 1.3M
- Earning Date
- AXTA 05-07-2025
- JAZZ 05-06-2025
- Dividend Yield
- AXTA N/A
- JAZZ N/A
- EPS Growth
- AXTA 83.38
- JAZZ 49.21
- EPS
- AXTA 2.05
- JAZZ 7.51
- Revenue
- AXTA $5,244,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- AXTA $2.69
- JAZZ $6.07
- Revenue Next Year
- AXTA $3.65
- JAZZ $4.26
- P/E Ratio
- AXTA $15.77
- JAZZ $14.40
- Revenue Growth
- AXTA 0.96
- JAZZ 5.76
- 52 Week Low
- AXTA $27.70
- JAZZ $95.49
- 52 Week High
- AXTA $41.66
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- AXTA 52.43
- JAZZ 48.94
- Support Level
- AXTA $30.89
- JAZZ $103.60
- Resistance Level
- AXTA $33.06
- JAZZ $108.72
- Average True Range (ATR)
- AXTA 0.85
- JAZZ 4.51
- MACD
- AXTA 0.11
- JAZZ 0.44
- Stochastic Oscillator
- AXTA 63.44
- JAZZ 49.55
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.